NL
New Leaf Venture Partners, L.L.C.
13F filer · CIK 0001631614Last filed Nov 14, 2025
Inactive · not filing 13F
13F portfolio value$43MU.S. long equity reported on 13F
Positions70 new · 1 closed
Net flow last quarter-$644KBuys minus sells
Top 10 positions weight100.0%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q3 2025Reported Nov 14, 20257 positions | |||||
| $16.7M | 38.82% | 0.97% | Not reported | Q1 2021 | |
| $13.5M | 31.38% | 2.24% | Not reported | Q3 2018 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $5.87M | 13.64% | 0.15% | Not reported | Q3 2018 |
| $3.6M | 8.37% | 0.18% | Not reported | Q4 2020 | |
| $1.65M | 3.83% | 7.87% | Not reported | Q3 2021 | |
| $1.01M | 2.33% | 0.32% | Not reported | Q1 2019 | |
| $702K | 1.63% | 2.75% | -30.0% | Q1 2020 | |
| Q2 2025Reported Aug 13, 20258 positions | |||||
| $20M | 37.74% | 78.58% | Not reported | Q1 2020 | |
| $13.5M | 25.51% | 0.98% | Not reported | Q1 2021 | |
| $11.7M | 22.04% | 2.17% | Not reported | Q3 2018 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $4.06M | 7.66% | 0.15% | Not reported | Q3 2018 |
| $1.8M | 3.40% | 0.22% | Not reported | Q4 2020 | |
| $1.12M | 2.11% | 7.92% | Not reported | Q3 2021 | |
| $475K | 0.90% | 0.34% | Not reported | Q1 2019 | |
| ITITRMIterum Therapeutics plc | $343K | 0.65% | 0.86% | Not reported | Q2 2018 |
| Q1 2025Reported May 13, 20259 positions | |||||
| $22.7M | 50.47% | 1.08% | Not reported | Q1 2021 | |
| $11.1M | 24.79% | 2.17% | Not reported | Q3 2018 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $4.73M | 10.53% | 0.15% | Not reported | Q3 2018 |
| $2.15M | 4.78% | 7.93% | Not reported | Q3 2021 | |
| $1.5M | 3.35% | 0.22% | Not reported | Q4 2020 | |
| $1.01M | 2.24% | 0.14% | Not reported | Q4 2022 | |
| $882K | 1.96% | 4.02% | Not reported | Q1 2020 | |
| ITITRMIterum Therapeutics plc | $424K | 0.95% | 1.00% | Not reported | Q2 2018 |
| $418K | 0.93% | 0.34% | Not reported | Q1 2019 | |
| Q4 2024Reported Feb 13, 20259 positions | |||||
| $30.4M | 40.64% | 2.30% | +10.5% | Q3 2018 | |
| $27.5M | 36.77% | 1.09% | -33.7% | Q1 2021 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $7.21M | 9.64% | 0.15% | Not reported | Q3 2018 |
| $3.17M | 4.24% | 63.63% | Not reported | Q3 2021 | |
| $1.96M | 2.61% | 0.23% | Not reported | Q4 2020 | |
| $1.89M | 2.53% | 0.14% | Not reported | Q4 2022 | |
| $1.42M | 1.89% | 79.01% | Not reported | Q1 2020 | |
| $642K | 0.86% | 0.34% | Not reported | Q1 2019 | |
| ITITRMIterum Therapeutics plc | $611K | 0.82% | 1.25% | Not reported | Q2 2018 |
Premium opens every quarter this fund has filed